Uso de Cannabis, Cognição e o Sistema Endocanabinóide no HIV
Understanding how co-morbidities in persons with HIV (PWH) such as substance use affect risk-taking, decision-making, and other cognitive behaviors is important given implications for everyday functioning and transmission risk. The high prevalence of cannabis use in PWH, medicinally and recreationally, may indicate disease severity, impart therapeutic benefits, or adverse consequences. In fact, cannabis is recommended to those with HIV to alleviate nausea, improve appetite, relieve pain, and lift mood. To-date, the consequences of cannabis use in PWH remain unclear as do potential interactions with HIV treatments. In healthy participants, heavy cannabis use is associated with cognitive deficits e.g., risky decision-making, response disinhibition and inattention, but pro-cognitive effects in PWH may exist at mild use levels due to its anti-inflammatory and anti-excitotoxic properties. Furthermore, little has been done to determine the effects of cannabis use on the endocannabinoid (EC) system in general or in PWH. This study will determine the effects of the two primary cannabis constituents (Δ9-tetrahydrocannabinol [THC], cannabidiol [CBD]) vs. placebo on risky decision-making, response inhibition, reward learning, temporal perception, and motivation, plus EC and homovanillic acid (HVA; a surrogate for dopamine activity) levels in HIV+ and HIV- subjects. Participants with infrequent cannabis use will undergo baseline cognitive testing and biomarker assays with antiretrovirals (ART) use quantified. They will be randomized to a 5-day course of either THC, CBD, or placebo and return for follow-up testing and re-assaying of ECs and HVA levels.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase inicial 1
Contactos e Locais
Locais de estudo
-
-
California
-
San Diego, California, Estados Unidos, 92103-8620
- UC San Diego Medical Center-Hillcrest
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria
- Aged 18-65
- Possess the capacity to provide informed consent to a set of neurobehavioral, neuromedical and cognitive assessment procedures. Individuals unable to provide such consent will not be enrolled into the study.
- Willing to confirm self-reported HIV using a rapid test: HIV status will be determined using the MedMira Rapid Test (Halifax, Nova Scotia, Canada). If the result differs from the participant's self-report a confirmatory Western Blot will be performed.
- Willing to abstain from cannabis for at least 1 week prior to the baseline visit and during the study. Although there is no definitive method for determining abstinence over this period, abstinence will be confirmed as best as possible by using an oral fluid testing device (Draeger 5000) employed by law enforcement officers to detect recent cannabis use. An oral fluid value of > 5ng suggests recent use, although in some cases it has been reported that individuals may show > 5ng up to 20 hours after use. Thus, should the oral fluid sample indicate > 5ng THC, the assessment may be canceled and rescheduled.
Exclusion Criteria
- Inability to provide informed consent
- Significant chronic renal disease (unrelated to HIV), significant chronic pulmonary disease (unrelated to HIV), or Hepatitis C Virus infection
- Head injury with loss of consciousness for greater than 30 minutes or resulting in neurologic complications
- Seizure disorder
- Demyelinating diseases or other non-HIV neurological disorders
- Pregnancy
- Acute or recent or previous clinically disabling stroke or previous cerebrovascular events
- Lifetime history of schizophrenia or other psychotic disorders, or bipolar disorder.
- Beck Depression Inventory-II (BDI-II) score is greater than or equal to 29 (severe depression) or suicidal ideas are endorsed on the BDI-II or a Center for Epidemiological Studies-Depression Scale (CES-D) subscale measuring suicidal ideation
- Substance use disorder (mild, moderate or severe) within the last 12 months
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: HIV-positive subjects
Adult human subjects seropositive for HIV-1 |
5-day course of orally-administered THC (dronabinol), 10 mg 5-day course of orally-administered CBD, 600 mg 5-day course of orally-administered placebo |
|
Comparador Ativo: Healthy Comparison Volunteers
Adult human subjects without HIV |
5-day course of orally-administered THC (dronabinol), 10 mg 5-day course of orally-administered CBD, 600 mg 5-day course of orally-administered placebo |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
change in Iowa Gambling Task score from baseline to post-intervention
Prazo: baseline and 5 days after drug initiation
|
This is an experimental measure and not a scale with specific anchor points. Lower scores reflect increased risk-taking |
baseline and 5 days after drug initiation
|
|
change in Human Temporal Bisection Task score from baseline to post-intervention
Prazo: baseline and 5 days after drug initiation
|
This is an experimental measure and not a scale with specific anchor points. Scores reflect fast or slow perception of timing. |
baseline and 5 days after drug initiation
|
|
change in Probabilistic Learning Task score from baseline to post-intervention
Prazo: baseline and 5 days after drug initiation
|
This is an experimental measure and not a scale with specific anchor points. Lower scores reflect poorer learning. |
baseline and 5 days after drug initiation
|
|
change in Progressive Ratio Task score from baseline to post-intervention
Prazo: baseline and 5 days after drug initiation
|
This is an experimental measure and not a scale with specific anchor points. Lower scores reflect lower motivation or willingness to work for a reward. |
baseline and 5 days after drug initiation
|
|
change in Continuous Performance Task score from baseline to post-intervention
Prazo: baseline and 5 days after drug initiation
|
This is an experimental measure and not a scale with specific anchor points. Lower scores reflect worse attention. |
baseline and 5 days after drug initiation
|
|
change in human Behavioral Pattern Monitor activity and exploration score from baseline to post-intervention
Prazo: baseline and 5 days after drug initiation
|
This is an experimental measure and not a scale with specific anchor points. Higher scores reflect motor hyperactivity and increased exploration. |
baseline and 5 days after drug initiation
|
|
change in prepulse inhibition percentage score from baseline to post-intervention
Prazo: baseline and 5 days after drug initiation
|
This is an experimental measure and not a scale with specific anchor points. Lower scores reflect worse sensorimotor gating. |
baseline and 5 days after drug initiation
|
|
change in cerebrospinal fluid (CSF) anandamide (AEA) quantity from baseline to post-intervention
Prazo: baseline and 5 days after drug initiation
|
This is an experimental measure and not a scale with specific anchor points. Lower AEA signifies less amounts of this endocannabinoid in the central nervous system. |
baseline and 5 days after drug initiation
|
|
change in cerebrospinal fluid (CSF) 2-Arachidonoylglycerol (2-AG) quantity from baseline to post-intervention
Prazo: baseline and 5 days after drug initiation
|
This is an experimental measure and not a scale with specific anchor points. Lower 2-AG signifies less amounts of this endocannabinoid in the central nervous system. |
baseline and 5 days after drug initiation
|
|
change in cerebrospinal fluid (CSF) homovanillic acid (HVA) quantity from baseline to post-intervention
Prazo: baseline and 5 days after drug initiation
|
This is an experimental measure and not a scale with specific anchor points. Lower HVA signifies less amounts of this dopamine metabolite in the central nervous system. |
baseline and 5 days after drug initiation
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Arpi Minassian, Ph.D., UC San Diego
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 210323
- R01DA051295 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .